I sit down with Dr. Mitrani, the Chief Scientific Officer for Organicell, a clinical stage biopharma company focused on regenerative medicine. Their leading product, Zofin is currently in early clinical trials for the treatment of COVID19. Eventually it may be a therapeutic for long haulers.
Key Talking Points
2:43 – Dr. Mitrani’s Journey to regenerative medicine
5:30 – From stem cells to nano medicine
8:12 – What is Zofin and how might it work?
9:46 – Pivoting into COVID19
11:42 – Following the science from stem cells to nano infusions
14:21 – Doing science is hard but we follow the data
19:59 – How following scientific data for years prepares you to pivot in response to crisis
25:40 – What trends have stood the test of time?
30:27 – How novel therapeutic spaces require novel approaches to product validation
34:11 – The work that is being done for COVID19 long-haulers
Music by Luke Goodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.